These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
507 related articles for article (PubMed ID: 25420994)
1. Asthma: pathogenesis and novel drugs for treatment. Olin JT; Wechsler ME BMJ; 2014 Nov; 349():g5517. PubMed ID: 25420994 [TBL] [Abstract][Full Text] [Related]
2. Severe asthma: advances in current management and future therapy. Barnes PJ J Allergy Clin Immunol; 2012 Jan; 129(1):48-59. PubMed ID: 22196524 [TBL] [Abstract][Full Text] [Related]
3. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM; J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355 [TBL] [Abstract][Full Text] [Related]
5. Difficult asthma: assessment and management, Part 2. Fanta CH; Long AA Allergy Asthma Proc; 2012; 33(4):313-23. PubMed ID: 22856632 [TBL] [Abstract][Full Text] [Related]
6. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715 [TBL] [Abstract][Full Text] [Related]
7. Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids. Domingo C; Moreno A; Mirapeix R Intern Med J; 2011 Jul; 41(7):525-36. PubMed ID: 21762333 [TBL] [Abstract][Full Text] [Related]
8. Pharmacologic interventions to reduce the risk of asthma exacerbations. O'Byrne PM Proc Am Thorac Soc; 2004; 1(2):105-8. PubMed ID: 16113421 [TBL] [Abstract][Full Text] [Related]
9. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents. Huffaker MF; Phipatanakul W Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581 [TBL] [Abstract][Full Text] [Related]
10. Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids. Naedele-Risha R; Dorinsky P; Craig TJ J Am Osteopath Assoc; 2001 Sep; 101(9):526-33. PubMed ID: 11575039 [TBL] [Abstract][Full Text] [Related]
11. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. Chung KF J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339 [TBL] [Abstract][Full Text] [Related]
12. How to set up a severe asthma service. McDonald VM; Vertigan AE; Gibson PG Respirology; 2011 Aug; 16(6):900-11. PubMed ID: 21692918 [TBL] [Abstract][Full Text] [Related]
13. Summaries for patients. Omalizumab therapy for patients with severe asthma. Ann Intern Med; 2011 May; 154(9):I28. PubMed ID: 21536934 [No Abstract] [Full Text] [Related]
14. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches. Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C; J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of omalizumab in severe asthma with fungal sensitisation: a case report. Di Stefano F; Cinti B; Antonicelli L Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):56-9. PubMed ID: 24702879 [TBL] [Abstract][Full Text] [Related]